July 4, 2014
Smart Money
Dear Reader
In its current European Venture & Growth Equity Bulletin London-based Go4Venture sees a broad upturn in the European venture capital market. This fits in with the news from Switzerland. At the 15th ICT Investors‘ Day a new club for business angels was announced.
A name has not yet been decided, but many prominent members have already signed up, including Thomas Dübendorfer, Dania Gerhardt, Pascal Mathis and Myke Näf.
Good news from the platform Investiere: through its members, it has been able to collect CHF500,000 for the start-up Sherpany in just three weeks. Overall, Sherpany has generated CHF 1.8 million.
And, finally, three reports that demonstrate that Swiss start-ups are not only attractive to angels, but also to established companies.
The internet start-up dodiz.com intends to show along with the news portal Watson a new route in native advertising.
Along with a subsidiary of Johnson & Johnson, GlycoVaxyn is beginning tests of a new vaccine against urinary tract infections.
And in the second quarter of 2015, Molecular Partners will begin the third and final phase of clinical testing of a new ophthalmic agent with US pharmaceutical company Allergan.
A good start to the summer and an enjoyable weekend.
Jost Dubacher
Managing Editor, startupticker.ch
News
.jpg "Startupfair 2014: Es ist angerichtet")
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
